Physician profile
Mukesh Kumar
NPI 1952807356
$3,666.11
in general payments reported to CMS, 2019-2025
18 companies · $1,431 in 2025
The $1,431 reported for 2025 was more than what 84% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $252 · 2023: $921 · 2024: $1,063 · 2025: $1,431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,414.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,413.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $930.66 | 2022-2025 | Tyrvaya, Ryzumvi |
| Harrow Eye, LLC | $603.48 | 2024-2025 | Vevye |
| Alcon Vision LLC | $542.20 | 2023-2025 | Eysuvis, Tryptyr, Clareon |
| Rxsight INC | $268.66 | 2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Abbvie INC. | $252.72 | 2023-2025 | |
| Bausch & Lomb Americas INC. | $224.01 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Sun Pharmaceutical Industries INC. | $180.47 | 2024-2025 | |
| Ocular Therapeutix, INC. | $152.91 | 2022-2023 | Dextenza |
| Tarsus Pharmaceuticals, INC. | $110.63 | 2024-2025 | Xdemvy |
| Biotissue Holdings INC. | $105.79 | 2023-2025 | |
| Dompe US, INC. | $77.72 | 2024-2025 | Oxervate |
| Amgen INC. | $75.21 | 2024-2025 | Tepezza |
| Glaukos Corporation | $38.08 | 2025 | Idosetr |
| Astellas Pharma US INC | $25.37 | 2024 | Izervay |
| Apellis Pharmaceuticals, INC. | $21.74 | 2025 | Syfovre |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $19.98 | 2023 | Flarex |
| New World Medical,INC. | $19.53 | 2025 | Ahmed Glaucoma Valve, Via360, Clearpath |
| Novartis Pharmaceuticals Corporation | $16.95 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mukesh Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.